Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:CALA NASDAQ:MIRM NYSE:MNK NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$9.61-1.6%$9.28$6.38▼$17.30$945.14M1.421.23 million shs760,168 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.05N/A-2.8212,887 shs2,201 shsMIRMMirum Pharmaceuticals$52.66-0.7%$47.37$36.20▼$54.23$2.63B0.97460,810 shs320,943 shsMNKMallinckrodt$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsOGIOrganigram Global$1.45-1.4%$1.34$0.85▼$2.08$196.89M1.36665,011 shs769,488 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-1.64%+7.68%-2.83%+25.13%-40.38%CALACalithera Biosciences0.00%0.00%-95.00%-90.00%-99.50%MIRMMirum Pharmaceuticals-0.66%+5.47%+8.67%+33.05%+46.60%MNKMallinckrodt0.00%0.00%0.00%0.00%0.00%OGIOrganigram Global-1.36%+2.11%-1.36%+40.78%-8.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals1.8175 of 5 stars3.51.00.00.01.51.70.6CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals2.927 of 5 stars2.60.00.04.21.71.70.6MNKMallinckrodtN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global0.9632 of 5 stars0.01.00.00.02.50.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.00Buy$18.1789.04% UpsideCALACalithera Biosciences 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 3.13Buy$65.5024.38% UpsideMNKMallinckrodt 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CALA, MIRM, OGI, MNK, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M5.50N/AN/A$0.77 per share12.48CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals$336.89M7.74N/AN/A$4.70 per share11.20MNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/AOGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A160.17N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)MNKMallinckrodtN/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/AOGIOrganigram Global-$33.39M$0.1014.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)Latest CALA, MIRM, OGI, MNK, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31N/AN/AN/A$107.91 millionN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.732.33CALACalithera BiosciencesN/AN/AN/AMIRMMirum Pharmaceuticals1.323.223.04MNKMallinckrodt1.180.570.31OGIOrganigram GlobalN/A3.421.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CALACalithera BiosciencesN/AMIRMMirum PharmaceuticalsN/AMNKMallinckrodt83.74%OGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%CALACalithera Biosciences6.60%MIRMMirum Pharmaceuticals14.36%MNKMallinckrodt0.30%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableMIRMMirum Pharmaceuticals14049.53 million42.42 millionOptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableOGIOrganigram Global860133.94 million133.82 millionOptionableCALA, MIRM, OGI, MNK, and AVDL HeadlinesRecent News About These CompaniesShareholders in Organigram Global (TSE:OGI) are in the red if they invested five years agoJuly 9 at 7:21 PM | finance.yahoo.comOrganigram Expands U.S. Presence with Hemp-Derived THC Beverage LaunchJuly 8, 2025 | tipranks.comOrganigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage PortfolioJuly 8, 2025 | financialpost.comFOrganigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage PortfolioJuly 8, 2025 | businesswire.comOrganigram Global (NASDAQ:OGI) Trading Up 2.9% - What's Next?July 5, 2025 | marketbeat.comOGI Organigram Global Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comTwo Sigma Investments LP Trims Holdings in Organigram Holdings Inc. (NASDAQ:OGI)June 13, 2025 | marketbeat.comJune 2025 Watchlist: Best Canadian Cannabis Stocks for GrowthMay 31, 2025 | marijuanastocks.comMEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14, 2025 | uk.investing.comOrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)May 12, 2025 | zacks.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comOrganigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comOrganigram Global Shares Recording of its OG Investor SessionApril 22, 2025 | businesswire.comOrganigram Global Announces Acquisition Of Collective Project Limited - Quick FactsApril 3, 2025 | nasdaq.comOrganigram Global Inc. (OGI.TO)April 2, 2025 | ca.finance.yahoo.comOrganigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQApril 2, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Geospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractCALA, MIRM, OGI, MNK, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$9.61 -0.16 (-1.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.46 -0.15 (-1.51%) As of 07/11/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/11/2025 11:51 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Mirum Pharmaceuticals NASDAQ:MIRM$52.66 -0.35 (-0.66%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$53.50 +0.85 (+1.60%) As of 07/11/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Mallinckrodt NYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Organigram Global NASDAQ:OGI$1.45 -0.02 (-1.36%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
